Promising Breakthrough for Efgartigimod Efficacy in Chronic Immune Thrombocytopenia
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial Efgartigimod, a novel therapy for primary immune thrombocytopenia (ITP), has shown significant efficacy in a phase 3 study. ITP, an autoimmune disorder causing low platelet counts and bleeding, was treated…
